^
    18h
    Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial • pMMR
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab)
    2d
    Structure-activity relationship and anticancer mechanism of febuxostat-1,2,3-triazole hybrids inducing DNA damage and apoptosis. (PubMed, Bioorg Chem)
    Among these, compound 10 h demonstrated the most potent antiproliferative effect (IC50 = 4.05 ± 0.67 μM), significantly outperforming the reference drug 5-fluorouracil (IC50 = 17.43 ± 4.66 μM), while exhibiting minimal toxicity toward normal liver L02 cells (IC50 > 40 μM). In vivo, 10 h significantly suppressed tumor growth in a HepG2 xenograft model without overt toxicity. Collectively, these findings establish 10 h as a highly potent and selective anticancer lead compound, acting via DNA damage-induced S-phase arrest and mitochondrial-mediated apoptosis, and highlight its potential for further development as a liver cancer therapeutic.
    Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
    |
    5-fluorouracil
    3d
    To investigate the efficacy and safety of irinotecan liposome combined with fluorouracil and oxaliplatin as neoadjuvant therapy for locally advanced rectal cancer (ChiCTR2600117281)
    P=N/A, N=34, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    5-fluorouracil • leucovorin calcium
    3d
    A Study on the Adherence of Patients with Nasopharyngeal Carcinoma to Oral Capecitabine Based on Digital Nudge (ChiCTR2500114952)
    P=N/A, N=140, Not yet recruiting, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New trial
    |
    capecitabine
    3d
    ED95 of Tegafur-5-Fluorouracil and Rimaclazol for respiratory depression during painless gastroscopy (ChiCTR2500113562)
    P=N/A, N=40, Not yet recruiting, Chizhou People's Hospital; Chizhou People's Hospital
    New trial
    |
    5-fluorouracil
    3d
    Safety,efficacy and mechanisms of envolimab and S-1 systemic therapy combined with intraperitoneal endostar in the treatment of gastric/gastric-oesophageal junction adenocarcinoma with malignant ascites in elderly patients over 70 years. (ChiCTR2500115706)
    P=N/A, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New trial
    |
    Teysuno (gimeracil/oteracil/tegafur) • Endostar (recombinant human endostatin)
    3d
    A randomized controlled study of CICAPLAST BAUME B5+ in the treatment of Capecitabine- related skin Adverse Reaction in cancer patients (ChiCTR2500115475)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University
    New trial
    |
    capecitabine
    3d
    Observational study on the arterial infusion of irinotecan liposome (Ⅱ), oxaliplatin, and 5- fluorouracil/leucovorin calcium combination regimen in the treatment of patients with pancreatic cancer (ChiCTR2500111898)
    P4, N=20, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New P4 trial
    |
    5-fluorouracil • leucovorin calcium
    3d
    Sintilimab Plus Systemic Chemotherapy With or Without Intraperitoneal Nab-Paclitaxel for Treatment-Naïve HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Phase III Randomized Controlled Trial (ChiCTR2600117422)
    P3, N=344, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-Sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    3d
    Individualized Adjuvant Treatment Decision for Locally Advanced Nasopharyngeal Carcinoma Guided by a Dynamic Therapeutic Response Prediction Model (RAIRI): A Multicenter Randomized Controlled Phase III Trial (ChiCTR2500112850)
    P3, N=651, Not yet recruiting, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical
    New P3 trial
    |
    capecitabine
    3d
    Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (ChiCTR2500115516)
    P2, N=39, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    oxaliplatin • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    3d
    A prospective, single-center, exploratory phase II clinical study of QL1706 combined with chemotherapy in the treatment of previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer. (ChiCTR2600116087)
    P2, N=32, Not yet recruiting, Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University
    New P2 trial
    |
    HER-2 overexpression • HER-2 amplification
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab)